Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.

Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, Lafont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Rajlic IL, Capka V, Jiang W, Wagner JP, Elliott G, Veloso A, Piel JC, Flaherty MM, Mansfield KG, Meseck EK, Rubic-Schneider T, London AS, Tschantz WR, Kurz M, Nguyen D, Bourret A, Meyer MJ, Faris JE, Janatpour MJ, Chan VW, Yoder NC, Catcott KC, McShea MA, Sun X, Gao H, Williams J, Hofmann F, Engelman JA, Ettenberg SA, Sellers WR, Lees E.

Cancer Discov. 2017 Sep;7(9):1030-1045. doi: 10.1158/2159-8290.CD-16-1414. Epub 2017 May 19.

2.

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.

Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, Zafari M, Kowal C, Yang G, Royo A, Jensen M, Dombrecht B, Meerschaert KR, Kolkman JA, Cromie KD, Mosher R, Gao H, Schuller A, Isaacs R, Sellers WR, Ettenberg SA.

MAbs. 2014;6(6):1560-70. doi: 10.4161/19420862.2014.975099.

3.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.

4.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.

Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15473-8. doi: 10.1073/pnas.1007428107. Epub 2010 Aug 16.

5.

Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene.

Brophy PD, Ostrom L, Lang KM, Dressler GR.

Development. 2001 Dec;128(23):4747-56.

6.

Structured methods for identifying and correcting potential human errors in space operations.

Nelson WR, Haney LN, Ostrom LT, Richards RE.

Acta Astronaut. 1998 Aug-Sep;43(3-6):211-22.

PMID:
11541925
7.

Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease.

Ostrom L, Tang MJ, Gruss P, Dressler GR.

Dev Biol. 2000 Mar 15;219(2):250-8.

8.

Lessons learned from investigations of therapy misadministration events.

Ostrom LT, Rathbun P, Cumberlin R, Horton J, Gastorf R, Leahy TJ.

Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):227-34.

PMID:
12118556

Supplemental Content

Loading ...
Support Center